Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 6

Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature

Authors Daniel J Abrams, Donald C Rojas, David B Arciniegas

Published Date November 2008 Volume 2008:4(6) Pages 1089—1109

DOI http://dx.doi.org/10.2147/NDT.S4120

Published 27 November 2008

Daniel J Abrams1, Donald C Rojas1, David B Arciniegas1,2

1Department of Psychiatry; 2Neurobehavioral Disorders Program, Departments of Psychiatry and Neurology, University of Colorado School of Medicine, Denver, CO, USA

Abstract: Considerable debate surrounds the inclusion of schizoaffective disorder in psychiatric nosology. Schizoaffective disorder may be a variant of schizophrenia in which mood symptoms are unusually prominent but not unusual in type. This condition may instead reflect a severe form of either major depressive or bipolar disorder in which episode-related psychotic symptoms fail to remit completely between mood episodes. Alternatively, schizoaffective disorder may reflect the co-occurrence of two relatively common psychiatric illnesses, schizophrenia and a mood disorder (major depressive or bipolar disorder). Each of these formulations of schizoaffective disorder presents nosological challenges because the signs and symptoms of this condition cross conventional categorical diagnostic boundaries between psychotic disorders and mood disorders. The study, evaluation, and treatment of persons presently diagnosed with schizoaffective may be more usefully informed by a dimensional approach. It is in this context that this article reviews and contrasts the categorical and dimensional approaches to its description, neurobiology, and treatment. Based on this review, an argument for the study and treatment of this condition using a dimensional approach is offered.

Keywords: schizoaffective disorder, schizophrenia, bipolar disorder, manic-depressive disorder

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Factors associated with inadequate diagnosis of COPD: On-Sint cohort analysis

Fernández-Villar A, López-Campos JL, Represas Represas C, Marín Barrera L, Leiro Fernández V, López Ramírez C, Casamor R

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:961-967

Published Date: 18 May 2015

Are calcifying microvesicles another analogous substructure of calcifying nanoparticles?

Atughonu TC, Arja SB, Shiekh FA

International Journal of Nanomedicine 2013, 8:4673-4676

Published Date: 5 December 2013

Development of PLGA-based itraconazole injectable nanospheres for sustained release

Bian X, Liang S, John J, Hsiao CH, Wei X, Liang D, Xie H

International Journal of Nanomedicine 2013, 8:4521-4531

Published Date: 21 November 2013

Preparation and characterization of gadolinium-loaded PLGA particles surface modified with RGDS for the detection of thrombus

Zhang Y, Zhou J, Guo D, Ao M, Zheng Y, Wang Z

International Journal of Nanomedicine 2013, 8:3745-3756

Published Date: 1 October 2013

Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate-release pellets supported on SBA-15 mesoporous silica [Erratum]

Wang Z, Chen B, Quan G, Li F, Wu Q, Dian L, Dong Y, Li G, Wu C

International Journal of Nanomedicine 2013, 8:627-628

Published Date: 7 February 2013

Letter to the editor

Ralla B, Holtmann C, Geerling G

Clinical Ophthalmology 2013, 7:243-246

Published Date: 5 February 2013

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2013, 7:129-130

Published Date: 16 January 2013

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Improved pharmacokinetics and reduced toxicity of brucine after encapsulation into stealth liposomes: role of phosphatidylcholine

Chen J, Yan GJ, Hu RR, Gu QW, Chen ML, Gu W, Chen ZP, Cai BC

International Journal of Nanomedicine 2012, 7:3567-3577

Published Date: 26 July 2012